Whitehawk Therapeutics Highlights Promising PTK7 Findings at Oncology Conference

Whitehawk Therapeutics Advances PTK7 Research at Major Oncology Conference

Whitehawk Therapeutics, Inc., an innovative player in the oncology therapeutics landscape, recently showcases significant findings regarding Protein Tyrosine Kinase 7 (PTK7) at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Collaborating with Tempus AI, Whitehawk analyzes over 157,000 tumor samples, revealing that PTK7 is expressed in approximately 70% of solid tumors. This positions PTK7 as the third most highly expressed tumor marker among antibody-drug conjugate (ADC) targets, trailing only behind the widely recognized HER2 and HER3. This extensive research underscores the critical role PTK7 may play in the future of targeted cancer therapies.

The findings highlight that median PTK7 mRNA expression is particularly pronounced in several cancers, including endometrial, ovarian, head and neck, non-small cell lung cancer (NSCLC), and breast tumors, with expression levels ranging from 6.7 to 7.4. Importantly, the expression of PTK7 remains stable across various histologic subtypes, stages of disease, and metastatic statuses. This stability reinforces the potential of PTK7 as a pan-tumor target, enhancing its attractiveness for the development of targeted therapies. Grace Dy, MD, emphasizes the translational potential of these findings, which could pave the way for new treatment options for patients with diverse solid tumors.

The comparative analysis of PTK7 expression levels, which are comparable to established ADC targets like HER2 and Trop-2, further illustrates the clinical relevance of this marker. As Whitehawk Therapeutics continues to develop its PTK7-directed ADC candidate, HWK-007, the absence of currently approved PTK7-directed ADCs presents a unique opportunity. The company is positioned to explore this promising target in its mission to create innovative cancer treatments that could significantly impact patient outcomes.

In addition to the conference presentation, Whitehawk's emphasis on PTK7 aligns with the broader trend in oncology towards identifying and targeting specific biomarkers to enhance the efficacy of treatments. The findings presented at the conference not only bolster the company's research initiatives but also contribute to the growing body of evidence that supports the potential of targeted therapies in oncology. As Whitehawk moves forward, its focus on PTK7 may lead to groundbreaking advancements in cancer treatment modalities.